QGEN$43.105
Chart
Performance
Key Stats
AI QGEN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyQIAGEN demonstrates solid fundamental performance, particularly in profitability and cash flow, supported by positive thematic tailwinds in diagnostics. However, elevated valuation metrics and mixed short-term technical signals warrant a balanced approach.
Thematic
QIAGEN is well-positioned within the growing molecular diagnostics and life sciences sectors, benefiting from increased demand for testing and research solutions. The company's diverse offerings provide resilience across various end-markets.
Fundamental
QIAGEN exhibits strong profitability and a healthy balance sheet, characterized by robust cash flow generation. While revenue growth has moderated, operating efficiency remains a key strength.
Technical
QIAGEN's stock is in an uptrend, trading above key moving averages, but momentum indicators suggest potential overbought conditions and a need for consolidation. Support levels are present, but resistance could limit near-term upside.
| Factor | Score |
|---|---|
| Healthcare & Diagnostics Demand | 85 |
| Innovation in Life Sciences | 78 |
| Global Health Trends | 70 |
| Competitive Landscape | 65 |
| Regulatory Environment | 77 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 70 |
| Growth | 40 |
| Balance Sheet Health | 85 |
| Cash Flow | 90 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Momentum | 55 |
| Volume Confirmation | 70 |
| Support & Resistance | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Consistent Earnings Growth
The company has a strong track record of beating EPS estimates. For instance, in Q2 2024, reported EPS was 0.55 against an estimate of 0.5, with a positive surprise of 9.95%. This trend indicates robust earnings generation capabilities.
Improving Valuation Metrics
The TTM P/E ratio has improved from 40.0 to 32.5 (2023) and further down to 26.2 (2022), suggesting the stock is becoming more attractively valued relative to its earnings. The forward P/E for 2025 is projected to be around 95.8, which, while high, may be justified if growth expectations are met.
Bearish Points (7)
High Forward P/E Ratio
The projected P/E for 2025 is high (95.8), and even the TTM P/E is 40.0. This suggests that current market expectations are very high, and any disappointment in future earnings could lead to a significant price correction. The P/S ratio of 18.5 in Q4 2024 is also notably high.
Slowing Revenue Growth
Annual revenue has shown a declining trend from $2.25 billion in 2021 to $1.98 billion in 2024. This deceleration in top-line growth, coupled with negative net income in Q2 2024 (-$183.46 million), raises concerns about future expansion and profitability.
Calendar
July 2025
2
Ex-Dividend Date
July 2025
10
Next Dividend Date
August 2025
6
Next Earnings Date
H: $0.62
A: $0.60
L: $0.60
H: 526.00M
A: 523.67M
L: 520.00M
Profile
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Seasonals
Price Target
50.57 USD
The 39 analysts offering 1 year price forecasts for QGEN have a max estimate of 55.00 and a min estimate of 45.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Global leader in life science tools, diagnostics, and laboratory products; direct competitor to Qiagen in various segments including sample preparation, molecular diagnostics, and analytical instruments.
Weight: 95
Diversified science and technology conglomerate with significant presence in diagnostics and life sciences, offering a broad range of instruments, consumables, and services that compete with or complement Qiagen's offerings.
Weight: 92
Dominant player in next-generation sequencing (NGS) technology; Qiagen provides sample preparation and bioinformatics solutions that are critical for Illumina's platforms, making them both partners and indirect competitors.
Weight: 90
A global pharmaceutical and diagnostics company, a major competitor in the molecular diagnostics space with its own comprehensive portfolio of tests and instruments.